NYSE:BMY - Bristol-Myers Squibb Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $46.81 -0.49 (-1.04 %) (As of 05/26/2019 06:55 AM ET)Previous Close$46.81Today's Range$46.78 - $47.5452-Week Range$44.30 - $63.69Volume9.47 million shsAverage Volume14.26 million shsMarket Capitalization$76.57 billionP/E Ratio11.76Dividend Yield3.46%Beta0.77 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Receive BMY News and Ratings via Email Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSE:BMY Previous Symbol CUSIP11012210 CIK14272 Webhttp://www.bms.com/ Phone212-546-4000Debt Debt-to-Equity Ratio0.37 Current Ratio1.93 Quick Ratio1.79Price-To-Earnings Trailing P/E Ratio11.76 Forward P/E Ratio11.20 P/E Growth2.22 Sales & Book Value Annual Sales$22.56 billion Price / Sales3.39 Cash Flow$4.3262 per share Price / Cash Flow10.82 Book Value$9.36 per share Price / Book5.00Profitability EPS (Most Recent Fiscal Year)$3.98 Net Income$4.92 billion Net Margins22.23% Return on Equity48.72% Return on Assets19.89%Miscellaneous Employees23,300 Outstanding Shares1,635,710,000Market Cap$76.57 billion Next Earnings Date7/25/2019 (Estimated) OptionableOptionable Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions What is Bristol-Myers Squibb's stock symbol? Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY." How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb? Bristol-Myers Squibb declared a quarterly dividend on Friday, March 8th. Investors of record on Friday, April 5th will be given a dividend of $0.41 per share on Wednesday, May 1st. This represents a $1.64 annualized dividend and a yield of 3.50%. The ex-dividend date of this dividend is Thursday, April 4th. View Bristol-Myers Squibb's Dividend History. How were Bristol-Myers Squibb's earnings last quarter? Bristol-Myers Squibb Co (NYSE:BMY) announced its quarterly earnings data on Thursday, April, 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.01. The biopharmaceutical company earned $5.92 billion during the quarter, compared to analysts' expectations of $5.72 billion. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The company's revenue was up 14.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.94 earnings per share. View Bristol-Myers Squibb's Earnings History. When is Bristol-Myers Squibb's next earnings date? Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Bristol-Myers Squibb. What guidance has Bristol-Myers Squibb issued on next quarter's earnings? Bristol-Myers Squibb issued an update on its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus estimate of $4.18. Bristol-Myers Squibb also updated its FY 2019 guidance to $4.10-4.20 EPS. What price target have analysts set for BMY? 16 brokerages have issued 1 year price targets for Bristol-Myers Squibb's stock. Their forecasts range from $46.36 to $67.00. On average, they expect Bristol-Myers Squibb's stock price to reach $57.1046 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Price Targets for Bristol-Myers Squibb. What is the consensus analysts' recommendation for Bristol-Myers Squibb? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bristol-Myers Squibb. Has Bristol-Myers Squibb been receiving favorable news coverage? Media coverage about BMY stock has trended positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Are investors shorting Bristol-Myers Squibb? Bristol-Myers Squibb saw a increase in short interest in April. As of April 30th, there was short interest totalling 91,485,556 shares, an increase of 18.1% from the April 15th total of 77,458,472 shares. Based on an average daily volume of 17,111,018 shares, the short-interest ratio is currently 5.3 days. Approximately 5.6% of the shares of the company are sold short. View Bristol-Myers Squibb's Current Options Chain. Who are some of Bristol-Myers Squibb's key competitors? Some companies that are related to Bristol-Myers Squibb include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Celgene (CELG), Bayer (BAYRY), Shire (SHPG) and Zoetis (ZTS). What other stocks do shareholders of Bristol-Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), Chicago Bridge & Iron (CBI), Diebold Nixdorf (DBD), AT&T (T), General Electric (GE), Bank of America (BAC), Gilead Sciences (GILD), Pfizer (PFE), KKR & Co Inc (KKR) and Intel (INTC). Who are Bristol-Myers Squibb's key executives? Bristol-Myers Squibb's management team includes the folowing people: Dr. Giovanni Caforio, Chairman & CEO (Age 54)Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57) Who are Bristol-Myers Squibb's major shareholders? Bristol-Myers Squibb's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (7.67%), BlackRock Inc. (6.58%), FMR LLC (2.50%), Geode Capital Management LLC (1.48%), Northern Trust Corp (1.38%) and Primecap Management Co. CA (1.33%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Joseph C Caldarella, Karen Murphy Santiago, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb. Which major investors are selling Bristol-Myers Squibb stock? BMY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Gyroscope Capital Management Group LLC, Los Angeles Capital Management & Equity Research Inc., Manning & Napier Group LLC, Clearbridge Investments LLC, Hexavest Inc. and OppenheimerFunds Inc.. View Insider Buying and Selling for Bristol-Myers Squibb. Which major investors are buying Bristol-Myers Squibb stock? BMY stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Charles Schwab Investment Management Inc., Renaissance Technologies LLC, Nordea Investment Management AB, Geode Capital Management LLC, Westfield Capital Management Co. LP, Primecap Management Co. CA and Loomis Sayles & Co. L P. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb. How do I buy shares of Bristol-Myers Squibb? Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Bristol-Myers Squibb's stock price today? One share of BMY stock can currently be purchased for approximately $46.81. How big of a company is Bristol-Myers Squibb? Bristol-Myers Squibb has a market capitalization of $76.57 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe. What is Bristol-Myers Squibb's official website? The official website for Bristol-Myers Squibb is http://www.bms.com/. How can I contact Bristol-Myers Squibb? Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected] MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 919 (Vote Outperform)Underperform Votes: 850 (Vote Underperform)Total Votes: 1,769MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What does EPS mean? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.